Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 6/20 | 0.45 |
| ▸ | SPR | P35270 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 5/20 | 0.39 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | SCD | O00767 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2798561 | 0.91 | SMO (0.44) | SMOSPRALDH1A1L3MBTL1SCD5 | |
| SCHEMBL2800581 | 0.89 | SMO (0.40) | SMOSPRALDH1A1L3MBTL1SCD5 | |
| SCHEMBL2801085 | 0.84 | PDE4B (0.44) | SPRALDH1A1L3MBTL1SCD5 | |
| SCHEMBL2800844 | 0.84 | SPR (0.42) | SPRALDH1A1L3MBTL1SCD5SCD | |
| SCHEMBL2801606 | 0.83 | PDE4B (0.48) | SPRALDH1A1L3MBTL1 | |
| SCHEMBL2800955 | 0.83 | SPR (0.41) | SPRALDH1A1L3MBTL1SCD5MGLL | |
| SCHEMBL2801102 | 0.82 | SIRT5 (0.50) | SPRALDH1A1L3MBTL1MGLL | |
| SCHEMBL2798467 | 0.82 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1 | |
| SCHEMBL2798969 | 0.81 | SCD5 (0.44) | SPRALDH1A1L3MBTL1SCD5SCD | |
| SCHEMBL2799831 | 0.81 | ALDH1A1 (0.47) | SPRALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206714-B1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8729264-B2 | Agent for prevention and/or treatment of skin diseases | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-05-20 | — | — | US | disclosed |
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2206714-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | Kyowa Hakko Kirin Co., Ltd. (JP) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | TYR, CUTA, SERPINB1 | SMO 1649/4885SPR 2955/4885ALDH1A1 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.